Indeed Patterson has no placebo arm in his long hauler

New Post Public Reply Private Reply Replies (3) Message Board
havasu78 kabonk #97689
522
Indeed Patterson has no placebo arm in his long hauler effort.

And Cytodyn's long hauler does indeed have a placebo arm.

What is remarkable about Patterson is that he can jump into chaos, innovate some clinical lab tests, and then offer a coherent theory.

I have no experience in medical diagnostics, but Patterson's disruptive technological and theoretical work seems quite unusual.

Maybe Patterson is full of hot air, but I don't think so.

The worst criticism that i can make of Patterson's work is that his original claims that "Covid is a RANTES disease" have not been confirmed, or at least not that I know of.

Surely someone must have tested the Patterson's RANTES hypothesis of sever covid.

Another disruptive leap by Patterson is his peer reviewed results on his long hauler index. Again, this seems like something that someone else could test. Maybe no one else can test this because it requires simultaneous blood measurements of 14 different cytokines. Probably Patterson's kit is the only thing that can do that on one 4 milliliter blood sample. Maybe no one else trys this because not using Patterson's kit requires too much blood and perhaps too many different clinical labs.

And now I see a news report that summarizes Patterson's efforts in the Patterson/Yo trial.

https://www.msn.com/en-us/sports/other/new-tr...vi-AAMwGth

The news editors who made this video have produced a remarkable document.

Patterson is on screen for less than twenty seconds speaking for perhaps a total of four sentences.

Patterson says:

Long hauler is caused by migration of cells to different parts of the body. The migrating cells have spike protein debris inside of them. When the migrating cells reach random body tissues, the immune system mounts an attack and the resulting inflammation causes long hauler symptoms.

Prescription statins reduce these effects because they prevent the migrating cells from binding to blood vessels so the migrating cells can't get into the tissues and cause inflammation.

Prescription CCR5 antagonists (Patterson is using maraviroc at the moment) prevent the migrating cells from migrating.

I suspect that there are no other scientists who believe Patterson's long hauler theory.

Patterson's long hauler theory, as expressed in this news video, is so specific and so compact that it strains credulity.

Patterson's blood test data supports his theory. He found spike protein residue inside of a specific kind of immune cell that is well known to migrate throughout all tissues in the body. I think it is also well known that the drugs Patterson is using have preciesely the effects that Patterson describes.

The news video is from a San Francisco station. Golden Gate bridge is in the background.

I think it us totally impossible that these news reporters edited this video without a great deal of personal help from Patterson. The brevity and specificity of Patterson's comments in the video is startling.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

NoBS.tech Secures Premier Partner Status with Datadog

Updated Category News Views 191

NoBS.tech Achieves Premier Partner Status with Datadog NoBS.tech, a firm dedicated entirely to Datadog consulting, has proudly announced its achievement of Premier Partner status within the Datadog Partner Network (DPN). This milestone elevates NoBS.tech to the highest level of partnership available in the program, showcasing its commitment to excellence in service...

Continue Reading
Investor Sentiment Shifts: Dollars Up, Bonds Down Amid Turmoil

Updated Category News Views 177

Investor Perspectives from the Latest Bank of America Survey According to recent insights gathered by Bank of America, investor sentiment is increasingly focused on the US dollar and equities, showcasing a bullish outlook, while caution looms over other investment classes. This recent revelation stems from their comprehensive Global Fund Manager Survey. Cash Holdings and...

Continue Reading
Midea Unveils Green Innovations at Chillventa 2024 Exhibition

Updated Category News Views 495

Innovative Sustainability at Chillventa 2024 Midea, a prominent leader in smart appliances, showcased groundbreaking sustainable technologies at Chillventa 2024. With a booth themed "Green Vision Blue Future," the company emphasized its commitment to low carbon and energy-efficient solutions. This exhibition became a vital platform for Midea to display its innovative...

Continue Reading
Emini Futures Overview: Navigating Market Trends and Strategies

Updated Category News Views 148

Emini S&P Futures Analysis The Emini S&P futures recently faced a significant shift as they broke through strong support levels between 6850 and 6840. This event issued a short-term sell signal, setting a target towards the 6810 and 6805 levels. The market dipped to as low as 6748 overnight, indicating a bearish trend. Traders should keep an eye on the potential support...

Continue Reading
Current Water Technologies Reports Q2 2024 Financial Results

Updated Category News Views 122

Current Water Technologies Reports Q2 2024 Financial Results Current Water Technologies Inc. (TSX-V: WATR) has released its financial results for the three months ending June 30, 2024. This report provides an overview of the company's performance in the second quarter, highlighting key financial metrics that shed light on its operations. Financial Highlights for the...

Continue Reading